SCHEMBL5010552

SCHEMBL5010552

Cc1cccc(C)c1-n1nc(CC(C)C)cc1Nc1ccccc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
GFER P55789 1/20 0.47
MEN1 O00255 3/20 0.47
PTGS2 P35354 3/20 0.47
AKR1C3 P42330 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
HIF1A Q16665 2/20 0.47
AKR1B10 O60218 2/20 0.47
ABCB11 O95342 2/20 0.47
CHRM1 P11229 2/20 0.47
PTGS1 P23219 2/20 0.47
AKR1C2 P52895 2/20 0.47
AKR1C1 Q04828 2/20 0.47
TRPA1 O75762 1/20 0.47
DHFR P00374 1/20 0.47
MPO P05164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5012025 0.85 MEN1 (0.50) MAPTGFERMEN1PTGS2AKR1C3
SCHEMBL5005267 0.80 MAPK14 (0.53) MAPTGFERMEN1PTGS2AKR1C3
SCHEMBL5005347 0.80 KCNJ6 (0.48) MAPTGFERMEN1PTGS2AKR1C3
SCHEMBL5012002 0.78 ADORA1 (0.59) MAPTGFERMEN1KMT2ALMNA
SCHEMBL14600673 0.73 DHODH (0.47) MAPTGFERMEN1PTGS2AKR1C3
SCHEMBL5007746 0.72 GFER (0.51) MAPTGFERMEN1PTGS2AKR1C3
SCHEMBL5007738 0.72 ADORA1 (0.50) GFERADORA3HPGDADORA1
SCHEMBL5012012 0.70 MAPK14 (0.50) LMNACLCN2
SCHEMBL5008346 0.70 GFER (0.80) MAPTGFERMEN1KMT2ALMNA
SCHEMBL4668570 0.70 GFER (0.42) MAPTGFERMEN1PTGS2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 MAPT 2420/4885GFER 1604/4885MEN1 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.